In vivo cell therapy technology advances with Ensoma’s Twelve Bio acquisition

The concept of in vivo cell therapies moves two steps ahead with the announcements that Ensoma raised $85 million in a series B financing round and added a Cas12a gene editing system to its toolbox through the acquisition of Twelve Bio.

The acquisition marries Ensoma Inc.’s adenovirus delivery technology with a CRISPR gene editing machinery — a pairing designed to enable cell-selective genetic modifications of cells inside the body — and two Arix Bioscience plc (LSE:ARIX) portfolio companies. ...